A GLOBAL MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 3 REGISTRATIONAL STUDY OF
OLVEREMBATINIB (HQP1351) IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID
LEUKEMIA (POLARIS-2)
- Registry ID
- HQP1351CG301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ASCENTAGE PHARMA GROUP INC.
- Start date
- 2025-04-02
- Last update
- 2024-09-05
Conditions
Related clinical trials
- A RANDOMIZED PHASE II STUDY COMPARING
CYTARABINE + DAUNORUBICIN (7+3) VS (DAUNORUBICIN AND CYTARABINE) LIPOSOME,
CYTARABINE + DAUNORUBICIN + VENETOCLAX, AZACITIDINE + VENETOCLAX, AND
(DAUNORUBICIN AND CYTARABINE) LIPOSOME + VENETOCLAX IN PATIENTS AGED 59 OR
YOUNGER WHO ARE CONSIDERED HIGH-RISK (ADVERSE) ACUTE MYELOID LEUKEMIA AS
DETERMINED BY MYELOMATCH; A MYELOMATCH CLINICAL TRIAL
- A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS
CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK
ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL
- A PHASE IIIB, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF TOLERABILITY AND EFFICACY OF ORAL ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
- A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE ACTIVITY, SAFETY AND PHARMACOKINETICS OF LENALIDOMIDE (REVLIMID®) IN PEDIATRIC SUBJECTS FROM 1 TO <= 18 YEARS OF AGE WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
View on source registry